Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan (Yervoy RMP)
Sponsor: Bristol-Myers Squibb
Listed as NCT02402699, this observational or N/A phase trial focuses on Advanced Melanoma and Hepatitis B and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Feb 2022 — Jul 2024 [monthly]
Completed
Status: Unknown Status → Completed
-
Jan 2021 — Feb 2022 [monthly]
Unknown Status
▶ Show 5 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Feb 2020 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jun 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2017 [monthly]
Recruiting NA
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .